Phase Ib: To evaluate the safety and tolerability of administration of ATLCAR.CD30.CCR4 cells in subjects with CD30+ Hodgkin's Lymphoma. 2.1.2 Phase II: To estimate the progression free survival (PFS) in adult subjects with Hodgkin's Lymphoma following lymphodepletion and infusion of ATLCAR.CD30.CCR4 cells.
Thank you for your interest, but this study will start enrolling soon.
North Carolina (Statewide)
Natalie Grover
Lineberger Comprehensive Cancer Center
Clinical or Medical
Interventional
Cancer (Lymphoma)
23-2771
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
